NRAS and melanoma: The serine/threonine kinase BRAFV600E mutation that disrupts the KIT-NRAS-BRAF-MEK-ERK-CDK4/6-RB pathway (Figure 4) is almost always present in both CSD and non-CSD melanomas [398].